IrsiCaixa AIDS Research Institute, Germans Trias i Pujol University Hospital, Fight AIDS Foundation
BCG intravesical instillations play a key role in treating superficial bladder cancer by reducing recurrence and limiting progression. Despite its proven effectiveness, however, a significant proportion of patients are non-responders and so exposed to an increased risk of recurrence and progression. Unfortunately, no early response marker is available as yet in clinical practice. The objective is to identify factors that predict response to bladder treatment with BCG.